533 exam - Study guides, Class notes & Summaries

Exam 1: NSG533 / NSG 533 (Latest 2024 / 2025 Update) Advanced Pharmacology Exam| Questions and Verified Answers with Rationales | 100% Correct | Grade A - Wilkes Q: In order to determine how much T4 replacement a patient needs to re-establish a euthyroid state, the NP considers: 1. the TSH value 2. the patient's T4 3. the patient's body weight 4. the patient's gender Answer: 3. the patient's body weight Replacement is based on body weight and is usually calculated in kg. The patients weight is c...

Exam 2: NSG533 / NSG 533 (Latest 2024 / 2025 Update) Advanced Pharmacology Exam Review | Complete Guide with Questions and Verified Answers | 100% Correct - Wilkes Q: How does Tramadol work? Answer: It is a centrally acting synthetic opioid with weak SSRI/SNRI activity. Q: What are the daily dose limits for Tramadol? Answer: Maximum of 200mg per day. Q: What are the potential interactions of Tramadol? Answer: Increased risk of seizures with TCAs and other SSRIs, risk for serotonin syndrome. Q: W...

NSG 533 | NSG533 Exam 2 Questions and Answers Graded A+ | Latest 2024 | Wilkes NSG 533 | NSG533 Exam 2 Questions and Answers Graded A+ | Latest 2024 | Wilkes

Exam 3: NSG533 / NSG 533 (Latest 2024 / 2024 Update) Advanced Pharmacology Exam Review | Guide with Questions and Verified Answers | 100% Correct - Wilkes Q: Short-acting muscarinic antagonist (SAMA) Answer: Ipratropium Q: avoid co administration of ICS with which CYP3A4 inhibitors? (may cause cushing's) Answer: ritonavir, itraconazole, ketoconazole Q: lack of response to ICS may be indicative of what? Answer: CLCCl1 gene Q: LABAs Answer: Salmeterol Formoterol Vilanterol Q: LAMAs Answer: tiotro...

Exam 1: NSG533 / NSG 533 (Latest 2024 / 2025) Advanced Pharmacology Complete Review | Questions and Verified Answers | 100% Correct | Grade A - Wilkes Q: Histamine-2 Receptor Antagonists (cimetidine, famotidine, nizatidine, ranitidine) Answer: Decrease acid secretion by blocking histamine receptors in gastric parietal cells Relief from typical acute GERD symptoms and prophylactic More effective than antacids for chronic GERD but less effective than PPIs May be dosed intermittently or on schedule...

Exam 2: NSG533 / NSG 533 (Latest 2024 / 2025) Advanced Pharmacology Review | Questions and Verified Answers | 100% Correct | Grade A - Wilkes Q: NSAID use Nonselective COX-1 and COX-2 inhibitors (COX-2 does anti-inflammation) Precaution: GI issues, renal toxicity, antiplatelet effect No NSAID is better than others- but vary from patient to patient Best for: RA, menstrual cramps, postsurgical pain, bony metastasis Flat-dose curve response: higher doses aren't more effective than moderate doses b...

NSG533 / NSG 533 Exam 1 (Latest 2024 / 2025): Advanced Pharmacology | Questions and Verified Answers with Rationales | 100% Correct | Grade A - Wilkes

Exam 3: NSG533 / NSG 533 (Latest 2024 / 2025) Advanced Pharmacology Complete Review | Questions and Verified Answers | 100% Correct | Grade A - Wilkes Q: Long-acting Inhaled B2-agonists Answer: -Provide 12-24 hours of bronchodilation after single dose -Useful for nocturnal symptoms -Chronic treatment for asthma as ADD-ON therapy for patients not controlled on low-medium dose of ICS -Helps reduce ICS amount necessary for control *-Not to be used a monotherapy (risk for severe attack)* -Salmeterol...

Exam 1: NSG533 / NSG 533 (Latest 2024 / 2025 Update) Advanced Pharmacology Exam Review | Complete Guide with Questions and Verified Answers | 100% Correct - Wilkes Q: What are the goals set by ACE /ACCE and are they written in stone for all patients? Answer: Primary target for glycemic control is HbA1C Individualize HbA1C goal - based on...Duration of DM Age /life expectancy Comorbid conditions Known CVD or advanced comorbid conditionsHypoglycemic unawareness Individual patient considerations Q:...

NSG 533 (NSG533) Exam 2 | Advanced Pharmacology Exam 2 | Latest 2024 NSG 533 (NSG533) Exam 2 | Advanced Pharmacology Exam 2 | Latest 2024 NSG 533 (NSG533) Exam 2 | Advanced Pharmacology Exam 2 | Latest 2024